Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial

Research output: Contribution to journalArticlepeer-review


Colleges, School and Institutes


Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy and a leading cause of sudden cardiac death in a young population. ARVC is especially common in young athletes. Mutations in different desmosomal genes have been identified causing dysfunctional cell-cell contacts. Reduced myocardial expression of plakoglobin in cell-cell contact complexes appears to associate with disease manifestation in patients harbouring mutations within other cell-cell contact genes. Experimental data suggest that preload reduction may be a simple and effective intervention to prevent disease progression and ventricular arrhythmias in ARVC. This review discusses the potential effects of this innovative approach and describes the design of the first controlled trial of preload-reducing therapy in patients with ARVC.


Original languageEnglish
Pages (from-to)340-6
Number of pages7
JournalProgress in Biophysics and Molecular Biology
Issue number2-3
Publication statusPublished - 5 Sep 2012


  • Animals, Arrhythmogenic Right Ventricular Dysplasia, Clinical Trials as Topic, Disease Progression, Heart, Humans